Whitehouse Station, New Jersey 08889

  • HIV Infections


The purpose of this study is to see if it is safe and effective to give indinavir sulfate plus stavudine to HIV-infected patients who have already been treated with zidovudine.


Inclusion Criteria Concurrent Medication: Allowed: - Prophylaxis with aerosolized pentamidine, topical antifungals, TMP / SMX, dapsone, or isoniazid. Patients must have: - HIV infection. - CD4 count 50 - 500 cells/mm3. - Prior AZT use for more than 6 months OR documented intolerance to AZT with more than 6 months use of another anti-HIV therapy other than d4T or any protease inhibitor. - No active opportunistic infection or visceral Kaposi's sarcoma. NOTE: - Patients with hemophilia may be enrolled at discretion of investigator. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Symptomatic neuropathy. - Acute hepatitis. Concurrent Medication: Excluded: - Antiretrovirals other than specified in protocol. - Chronic therapy for an active opportunistic infection. - Immunosuppressive therapy. Prior Medication: Excluded: - Any prior protease inhibitor or d4T. - Any nucleoside analogs within 2 weeks prior to study entry. - Investigational agents or immunomodulators within 30 days prior to study entry. Required: - More than 6 months of prior AZT unless intolerant, in which case more than 6 months of another anti-HIV therapy (other than protease inhibitors or d4T).



Primary Contact:


Backup Contact:


Location Contact:

Whitehouse Station, New Jersey 08889
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 24, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.